Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Recalls, complaints & regulation

Arcturus Therapeutics Holdings (ARCT): clinical trials

Arcturus Therapeutics Holdings (ARCT) beyond its filings: 2 active clinical trials.

Arcturus Therapeutics Holdings' latest quarter

Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Arcturus Therapeutics Holdings have?

2 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.